SCHEMBL17596247

SCHEMBL17596247

NNC(=O)c1ccc(C(F)(F)F)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 1/20 0.53
KCNQ2 O43526 1/20 0.53
KCNE1 P15382 1/20 0.53
KCNQ1 P51787 1/20 0.53
KIF11 P52732 5/20 0.51
ALDH1A1 P00352 5/20 0.46
MAPT P10636 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
HDAC1 Q13547 3/20 0.45
HDAC6 Q9UBN7 2/20 0.45
BLM P54132 2/20 0.44
MPO P05164 1/20 0.44
CYP3A4 P08684 1/20 0.44
KDM5A P29375 1/20 0.44
GFER P55789 1/20 0.44
PMP22 Q01453 1/20 0.44
HIF1A Q16665 1/20 0.44
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.43
NSD2 O96028 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620917 1.00 KCNQ3 (0.53) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL25216423 0.86 TAS1R3 (0.56) KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1
SCHEMBL9859436 0.83 KIF11 (0.49) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL14214022 0.83 KIF11 (0.55) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL17623519 0.82 SLC6A3 (0.47) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL6578591 0.81 ALDH1A1 (0.50) KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1
SCHEMBL1031838 0.80 KIF11 (0.56) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL6416718 0.80 KIF11 (0.53) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL1128282 0.80 CES2 (0.59) KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1
SCHEMBL29717191 0.80 CES2 (0.59) KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US disclosed
US-12338243-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2025-06-24 US disclosed
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME CUREVERSE INCORPORATED (KR) 2025-06-19 US disclosed
EP-4495106-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2025-01-22 EP disclosed
WO-2023177146-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME 재단법인 대구경북첨단의료산업진흥재단 2023-09-21 WO disclosed
US-11584726-B2 Amino alcohol derivative, pharmaceutical composition and application thereof BEIJING FORELAND PHARMA CO., LTD. (CN) 2023-02-21 US disclosed
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
US-20220235062-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-07-28 US disclosed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 EP disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed
US-20210347745-A1 AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF BEIJING FORELAND PHARMA CO., LTD. (CN) 2021-11-11 US disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed
EP-3191488-B1 P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES JANSSEN PHARMACEUTICA NV (BE) 2019-08-14 EP disclosed
US-20180118749-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 US disclosed
EP-3191488-A1 P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES Janssen Pharmaceutica, N.V. (BE) 2017-07-19 EP disclosed
WO-2016039983-A1 P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES JANSSEN PHARMACEUTICA NV (BE) 2016-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235062-A1 P2X7 MODULATORS P2RX7, P2RX4, P2RX1 KCNQ3 264/4885KCNQ2 221/4885KCNE1 360/4885
US-20210347745-A1 AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SSB, HLA-DRB1, LCP2 KCNQ3 2092/4885KCNQ2 2532/4885KCNE1 3277/4885
US-12338243-B2 P2X7 modulators P2RX7, P2RX4, P2RX1 KCNQ3 264/4885KCNQ2 221/4885KCNE1 360/4885
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB KCNQ3 4747/4885KCNQ2 4731/4885KCNE1 4326/4885
US-20180118749-A1 P2X7 MODULATORS P2RX7, P2RX3, P2RX1 KCNQ3 613/4885KCNQ2 660/4885KCNE1 831/4885
US-11584726-B2 Amino alcohol derivative, pharmaceutical composition and application thereof SSB, HLA-DRB1, LCP2 KCNQ3 2092/4885KCNQ2 2532/4885KCNE1 3277/4885
US-20260001870-A1 INHIBITOR COMPOUNDS CES1, NCEH1, NR1H2 KCNQ3 2319/4885KCNQ2 2647/4885KCNE1 1391/4885
US-12448371-B2 Inhibitor compounds SERPINB1, MMP1, SSB KCNQ3 4747/4885KCNQ2 4731/4885KCNE1 4326/4885
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME PPARD, PPARG, PPARA KCNQ3 2780/4885KCNQ2 3981/4885KCNE1 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.